Bionomics Ltd Sp ADR (BMICY) 9.6000 $BMICY
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Malignant Mesothelioma Therapeutics Pipeline Review 2014 - Analysis of 13 Companies & 22 Drug Profiles
M2 - Tue Apr 22, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db52sm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - MedImmune, LLC - Aduro BioTech, Inc. - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Advantagene, Inc. - Y's Therapeutics Co., Ltd. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - AEOL-10150 - Ad5-SGE-REIC/Dkk3 Gene Therapy - BAY-949343 - BERTA - BIW-8962 - BNC-105 - Bivalent Bispecific Tribody - CRS-207 - Drug For Mesothelioma - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - FPI-01 - LY-3023414 - Monovalent Trispecific Tribody - Oshadi D - Oshadi D Oshadi R - SentoClone - VS-4718 - YP-223 - YP-3 - YS-110 - YYP-218 - tremelimumab For more information visit http://www.researchandmarkets.com/research/db52sm/malignant
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Bionomics Features at American Association for Cancer Research Annual Meeting
GlobeNewswire - Mon Apr 07, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) is delivering three poster presentations at the 105th Annual American Association for Cancer Research (AACR) meeting at the San Diego Convention Center this week.
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer
GlobeNewswire - Mon Feb 03, 6:30AM CST
-- 10 out of 15 patients with positive response in Phase I
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
Psoriasis - Pipeline Review, H1 2014: 110 Companies Profiled
M2 - Thu May 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p6vjq8/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 4SC AG - Acceleron Pharma, Inc. - Addex Therapeutics - Advancell - Advinus Therapeutics Ltd. - Affimed Therapeutics AG - Ajinomoto Pharmaceuticals Co., Ltd. - AlbireoPharma - Alcon, Inc. - Allozyne, Inc. - Almirall, S.A. - Amgen Inc. - Anacor Pharmaceuticals, Inc. - AnaptysBio, Inc. - AngioLab, Inc. - Apexigen, Inc. - ApoPharma Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Aurinia Pharmaceuticals Inc. - Avexxin AS - Basilea Pharmaceutica AG - Bionomics Limited - Brickell Biotech, Inc. - Can-Fite BioPharma Ltd. - Catabasis Pharmaceuticals, Inc. - Celgene Corporation - Cell Therapeutics, Inc. - Cellceutix Corporation - Celltrion, Inc. For more information visit http://www.researchandmarkets.com/research/p6vjq8/psoriasis
Cognitive Impairment - Pipeline Review, H1 2014: 40 Companies and 82 Drugs Profiled
M2 - Thu May 08, 3:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4kz65z/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cognitive Impairment and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved: - AGY Therapeutics, Inc. - AbbVie Inc. - Amarantus Bioscience Holdings, Inc. - Avineuro Pharmaceuticals, Inc. - Bionomics Limited - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celon Pharma Sp. z o.o. - CoMentis, Inc. - D-Pharm Ltd. - Dart NeuroScience LLC - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Heptares Therapeutics Ltd. - Intra-Cellular Therapies, Inc. - Merck & Co., Inc. - Merz Pharmaceuticals GmbH - Mithridion, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeuroDerm Ltd. - Novartis AG - Octapharma AG - Omeros Corporation - Pacific Northwest Biotechnology, LLC - Pfizer Inc. - Pherin Pharmaceuticals, Inc. - QR Pharma, Inc. - SK Biopharmaceuticals Co., Ltd. Drug Profiles: - MK-8931 - idursulfase - AQW-051 - GTS-21 - AVN-211 - tesamorelin acetate - eltoprazine - CHF-5074 - immune globulin (human) - ABT-126 - Peptide T - citicoline sodium - erteberel - ladostigil tartrate - sodium oligomannurarate - DAOI-B - levetiracetam - mifepristone - F-03 - Posiphen - GSK-933776 - roflumilast - ABT-560 - TTP-4000 - ITI-214 - HTL-9936 - SKL-15508 - BMS-933043 - AN-761 - PH-15 For more information visit http://www.researchandmarkets.com/research/4kz65z/cognitive
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
Epilepsy - Pipeline Review, H1 2014: 43 Companies and 97 Drugs Profiled
M2 - Wed May 07, 8:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/652dzz/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epilepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epilepsy and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - Acorda Therapeutics, Inc. - Advicenne Pharma - Aeolus Pharmaceuticals, Inc. - Aestus Therapeutics, Inc. - Allergan, Inc. - Anavex Life Sciences Corp. - Aniona ApS - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Bial - Portela & Ca, S.A. - Bio-Link Australia Pty. Ltd. - BioCrea GmbH - Bionomics Limited - Biovista Inc. - Celentyx Ltd. - Chong Kun Dang Pharmaceutical Corp. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Eisai Co., Ltd. - GW Pharmaceuticals plc - Glialogix, Inc. - Sun Pharmaceutical Industries Limited - UCB S.A. - Upsher-Smith Laboratories, Inc. - Vertex Pharmaceuticals Incorporated - Vichem Chemie Research Ltd. - XERIS Pharmaceuticals, Inc. - Zalicus Inc. Drug Profiles: - lacosamide - perampanel - eslicarbazepine acetate - diazepam - ADV-5803 - lacosamide - brivaracetam - carbamazepine - carisbamate - diazepam - eslicarbazepine acetate - lacosamide - everolimus - belnacasan - YKP-3089 - naluzotan - DP-VPA - selurampanel - ganaxolone - IPX-218 - topiramate - tonabersat - GWP-42006 - SUN-44 - INS-001 - PF-04895162 - CKD-903 - ANAVEX-2-73 - Antiepileptic Drugs - ANAVEX-19-144 For more information visit http://www.researchandmarkets.com/research/652dzz/epilepsy
Malignant Mesothelioma Therapeutics Pipeline Review 2014 - Analysis of 13 Companies & 22 Drug Profiles
M2 - Tue Apr 22, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/db52sm/malignant) has announced the addition of the "Malignant Mesothelioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Kyowa Hakko Kirin Co., Ltd. - Eli Lilly and Company - MedImmune, LLC - Aduro BioTech, Inc. - Bayer AG - Aeolus Pharmaceuticals, Inc. - Bionomics Limited - Biotecnol, Inc. - Advantagene, Inc. - Y's Therapeutics Co., Ltd. - SentoClone International AB - Verastem, Inc. - Formula Pharmaceuticals, Inc. Drug Profiles - AEOL-10150 - Ad5-SGE-REIC/Dkk3 Gene Therapy - BAY-949343 - BERTA - BIW-8962 - BNC-105 - Bivalent Bispecific Tribody - CRS-207 - Drug For Mesothelioma - Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - FPI-01 - LY-3023414 - Monovalent Trispecific Tribody - Oshadi D - Oshadi D Oshadi R - SentoClone - VS-4718 - YP-223 - YP-3 - YS-110 - YYP-218 - tremelimumab For more information visit http://www.researchandmarkets.com/research/db52sm/malignant
Global Metastatic Renal Cell Carcinoma Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 34 Drug Profiles
M2 - Tue Apr 22, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgdszp/metastatic_renal) has announced the addition of the "Metastatic Renal Cell Carcinoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Renal Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Renal Cell Carcinoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Renal Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Renal Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Novartis AG - Biocon Limited - Eisai Co., Ltd. - Exelixis, Inc. - Bionomics Limited - Jiangsu Hengrui Medicine Co., Ltd. - Panacea Biotec Limited - Rexahn Pharmaceuticals, Inc. - Debiopharm International S.A. - Acceleron Pharma, Inc. - Argos Therapeutics, Inc. - Cerulean Pharma, Inc. - Immutep S.A. - Syndax Pharmaceuticals, Inc. - TVAX Biomedical, Inc. - Kite Pharma, Inc. - Xiamen Amoytop Biotech Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Activartis Biotech GmbH - AlphaMab Co., Ltd Drug Profiles - cabozantinib (s)-malate - 177Lu-DOTA-cG250 - AGS-003 - AV0-113 - AZD-2014 - Anti-NY ESO-1 Lymphocytes Vaccine - Autologous Tumor Cell Vaccine [aldesleukin] - BNC-105-P - CRLX-101 - DC-AdGM-CAIX - Debio-0932 - Dendritic Cell Vaccine [aldesleukin] [bevacizumab] [interferon alfa-2b] - IBPM-002-BZ - IMP-321 - LY-2510924 - Mechanism of Action - Orellanine - Product Description - R&D Progress - RX-0201 - SHR-1020 - TVI-Kidney-1 - aldeluskin - bevacizumab biosimilar - bevacizumab biosimilar - bevacizumab biosmilar - dalantercept - decitabine romidepsin - entinostat - everolimus For more information visit http://www.researchandmarkets.com/research/jg...atic_renal
Bionomics Features at American Association for Cancer Research Annual Meeting
GlobeNewswire - Mon Apr 07, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) is delivering three poster presentations at the 105th Annual American Association for Cancer Research (AACR) meeting at the San Diego Convention Center this week.
BNC105 Phase II Renal Cancer Trial Results
GlobeNewswire - Tue Mar 18, 5:30PM CDT
Bionomics to Host Webcast at 6:30pm ET TODAY
Bionomics Wins Awards at Major BioPharma Asia Convention
GlobeNewswire - Thu Mar 13, 6:30AM CDT
Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.
Bionomics CEO to Present at ROTH Conference
GlobeNewswire - Mon Mar 10, 7:00AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) CEO and managing director Dr Deborah Rathjen will present a company update at the renowned 26th Annual ROTH Conference in Dana Point, California Monday, March 10, 2014 at 11am PDT at The Ritz Carlton.
BNC105 Phase I/II Trial Achieves a High Response Rate in Ovarian Cancer
GlobeNewswire - Mon Feb 03, 6:30AM CST
-- 10 out of 15 patients with positive response in Phase I
Latest Thyroid Cancer Pipeline Review
M2 - Tue Jan 28, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/zmc3df/thyroid_cancer) has announced the addition of the "Thyroid Cancer - Pipeline Review, H2 2013" report to their offering. 'Thyroid Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thyroid Cancer. Scope - A snapshot of the global therapeutic scenario for Thyroid Cancer. - A review of the Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Thyroid Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Takeda Pharmaceutical Company Limited - Bio-Path Holdings, Inc. - Eisai Co., Ltd. - Bayer AG - Bionomics Limited - Azaya Therapeutics Incorporated - Vascular Biogenics Ltd. - Biovista Inc. - Trophogen, Inc. - centrose llc - Ecrins Therapeutics SAS For more information visit http://www.researchandmarkets.com/research/zm...oid_cancer
Head And Neck Cancer - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5stc2x/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2013" report to their offering. 'Head And Neck Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Head And Neck Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Head And Neck Cancer. Scope - A snapshot of the global therapeutic scenario for Head And Neck Cancer. - A review of the Head And Neck Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Head And Neck Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Inovio Biomedical Corporation Gilead Sciences, Inc. GenVec, Inc. Piramal Healthcare Limited Bio-Path Holdings, Inc. Millennium Pharmaceuticals, Inc. Novartis AG Daewoong Pharmaceutical Co., Ltd. Taiho Pharmaceutical Co., Ltd. Takara Holdings Inc. Cell Therapeutics, Inc. CEL-SCI Corporation Advaxis, Inc. Bionomics Limited Northwest Biotherapeutics, Inc. Oncolytics Biotech Inc. Curis, Inc. Transgene SA Panacea Biotec Limited and many more.... For more information visit http://www.researchandmarkets.com/research/5s...d_and_neck About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cognitive Impairment - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jz9l5q/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment. Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment. - A review of the Cognitive Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Boehringer Ingelheim GmbH Eli Lilly and Company Athersys, Inc. GlaxoSmithKline plc Merck & Co., Inc. Avineuro Pharmaceuticals, Inc. Novartis AG Chiesi Farmaceutici SpA Laboratoires Pierre Fabre SA Pfizer Inc. Evotec Aktiengesellschaft Lupin Limited Bionomics Limited Paladin Labs Inc. Theratechnologies Inc. Suven Life Sciences Ltd. Mithridion, Inc. Upsher-Smith Laboratories, Inc. Celon Pharma Sp. z o.o. AGY Therapeutics, Inc. PsychoGenics, Inc. QR Pharma, Inc. Siena Biotech S.p.A. SeneXta Therapeutics SA Dart NeuroScience LLC and many more... For more information visit http://www.researchandmarkets.com/research/jz9l5q/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013
M2 - Tue Sep 03, 8:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/97xbhx/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013" report to their offering. 'Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD). Scope - A snapshot of the global therapeutic scenario for Attention Deficit Hyperactivity Disorder (ADHD). - A review of the Attention Deficit Hyperactivity Disorder (ADHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned DURECT Corporation Eli Lilly and Company Athersys, Inc. Dainippon Sumitomo Pharma Co., Ltd. Taisho Pharmaceutical Co., Ltd. Egalet a/s Samyang Corporation Pfizer Inc. Shire Plc Collegium Pharmaceutical, Inc. Bionomics Limited Cortex Pharmaceuticals, Inc. Chelsea Therapeutics, Inc. Yuyu Pharma, Inc. Hisamitsu Pharmaceutical Co., Inc. Theravance, Inc. Suven Life Sciences Ltd. Spectrum Pharmaceuticals, Inc. Curemark, LLC Supernus Pharmaceuticals, Inc. PsychoGenics, Inc. Intra-Cellular Therapies, Inc. Neos Therapeutics, Inc. KemPharm, Inc. For more information visit http://www.researchandmarkets.com/research/97...on_deficit About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epilepsy - Pipeline Review, H2 2013 Gives a Snapshot of the Global Therapeutic Scenario for Epilepsy
M2 - Mon Sep 02, 11:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/njthrp/epilepsy) has announced the addition of the "Epilepsy - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epilepsy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epilepsy. Epilepsy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Epilepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epilepsy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: -Acorda Therapeutics, Inc. -Allergan, Inc. -Anavex Life Sciences Corp. -Asklepios BioPharmaceutical, Inc. -Bial - Portela & Ca, S.A. -Bio-Link -Bionomics Limited -Biovista Inc. -Catalyst Pharmaceutical Partners, Inc. -Celentyx Ltd. -Concert Pharmaceuticals, Inc. -D-Pharm Ltd. -Eisai Co., Ltd. -GW Pharmaceuticals plc -H Lundbeck A/S -Knopp Neurosciences Inc. -Kyowa Hakko Kirin Co., Ltd. -Ligand Pharmaceuticals Incorporated -Lipicard Technologies Limited -Marinus Pharmaceuticals, Inc. -Neurelis, Inc. -Novartis AG -NsGene A/S -Pfizer Inc. -Snowdon Inc. -Sun Pharmaceutical Industries Limited -UCB Group -Upsher-Smith Laboratories, Inc. -Valeant Pharmaceuticals International -Vertex Pharmaceuticals Incorporated -Vichem Chemie Research Ltd. -XERIS Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/njthrp/epilepsy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bionomics Signs Option and License Agreement With Merck
GlobeNewswire - Wed Jul 31, 5:30AM CDT
Bionomics Limited (ASX:BNO) today announced an agreement with Merck, known as MSD outside the United States and Canada, to discover and develop novel small molecule candidates for the treatment of chronic pain, including neuropathic pain.
Bionomics Initiates IND-Enabling Studies With BNC101
GlobeNewswire - Mon Jul 29, 5:30AM CDT
Bionomics Limited (ASX:BNO) (ADR:BMICY) announced today that it has initiated IND-enabling pharmacology and toxicology.
